NMRD - ネマウラ・メディカル (Nemaura Medical Inc.)

NMRDのニュース

   Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®  2019/05/02 13:00:00 Benzinga
Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced it will allow third-party applications, such as diabetes management, exercise and nutrition focused apps royalty free access to SugarBEAT® CGM app data. As a result, users will be able to directly access SugarBEAT® generated glucose data through their preferred participating mobile aplications, empowering users with greater choice over when to use this data to better understand how food choices and other lifestyle factors impact glucose levels. This development is part of the Company's broader go-to-market strategy, which is being led by Dr. Fred Schaebsdau. Dr. Schaebsdau joined the Company earlier this year to advance the commercialization and business development of SugarBEAT®, building on his success with earlier CGM products at Abbott Diabetes Care and Dexcom Germany." Dr.
   Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®  2019/04/23 12:00:00 Benzinga
Loughborough, England , April 23, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®. The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,' in preparation for submission of its medical device application to the FDA for SugarBEAT®. The two studies consisted of 16 participants each, including both Type I and Type II diabetics. Participants in the first and second study ranged from ages 18-50 and 51-70, respectively. The studies were designed to ensure adequate information was captured for the diverse age groups expected to use SugarBEAT®. The objective of the two studies was to confirm that the user interface aspects of SugarBEAT® met …
   Nemaura Medical files for $250M mixed shelf  2019/03/27 20:55:04 Seeking Alpha
   Nemaura establishes SugarBEAT distribution in Middle East; shares up 4%  2019/03/12 14:42:27 Seeking Alpha
   22nd Century Group and Tenax Therapeutics among healthcare gainers; Ligand Pharmaceuticals and Endologix among the losers  2019/03/06 16:06:16 Seeking Alpha
   Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®  2019/05/02 13:00:00 Benzinga
Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced it will allow third-party applications, such as diabetes management, exercise and nutrition focused apps royalty free access to SugarBEAT® CGM app data. As a result, users will be able to directly access SugarBEAT® generated glucose data through their preferred participating mobile aplications, empowering users with greater choice over when to use this data to better understand how food choices and other lifestyle factors impact glucose levels. This development is part of the Company's broader go-to-market strategy, which is being led by Dr. Fred Schaebsdau. Dr. Schaebsdau joined the Company earlier this year to advance the commercialization and business development of SugarBEAT®, building on his success with earlier CGM products at Abbott Diabetes Care and Dexcom Germany." Dr.
   Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®  2019/04/23 12:00:00 Benzinga
Loughborough, England , April 23, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®. The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,' in preparation for submission of its medical device application to the FDA for SugarBEAT®. The two studies consisted of 16 participants each, including both Type I and Type II diabetics. Participants in the first and second study ranged from ages 18-50 and 51-70, respectively. The studies were designed to ensure adequate information was captured for the diverse age groups expected to use SugarBEAT®. The objective of the two studies was to confirm that the user interface aspects of SugarBEAT® met …
   Nemaura Medical files for $250M mixed shelf  2019/03/27 20:55:04 Seeking Alpha
   Nemaura establishes SugarBEAT distribution in Middle East; shares up 4%  2019/03/12 14:42:27 Seeking Alpha
   22nd Century Group and Tenax Therapeutics among healthcare gainers; Ligand Pharmaceuticals and Endologix among the losers  2019/03/06 16:06:16 Seeking Alpha
   Nemaura Announces Open-Source Software for its Continuous Glucose Monitor SugarBEAT®  2019/05/02 13:00:00 Benzinga
Loughborough, England , May 02, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced it will allow third-party applications, such as diabetes management, exercise and nutrition focused apps royalty free access to SugarBEAT® CGM app data. As a result, users will be able to directly access SugarBEAT® generated glucose data through their preferred participating mobile aplications, empowering users with greater choice over when to use this data to better understand how food choices and other lifestyle factors impact glucose levels. This development is part of the Company's broader go-to-market strategy, which is being led by Dr. Fred Schaebsdau. Dr. Schaebsdau joined the Company earlier this year to advance the commercialization and business development of SugarBEAT®, building on his success with earlier CGM products at Abbott Diabetes Care and Dexcom Germany." Dr.
   Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®  2019/04/23 12:00:00 Benzinga
Loughborough, England , April 23, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD ), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®. The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,' in preparation for submission of its medical device application to the FDA for SugarBEAT®. The two studies consisted of 16 participants each, including both Type I and Type II diabetics. Participants in the first and second study ranged from ages 18-50 and 51-70, respectively. The studies were designed to ensure adequate information was captured for the diverse age groups expected to use SugarBEAT®. The objective of the two studies was to confirm that the user interface aspects of SugarBEAT® met …
   Nemaura Medical files for $250M mixed shelf  2019/03/27 20:55:04 Seeking Alpha
   Nemaura establishes SugarBEAT distribution in Middle East; shares up 4%  2019/03/12 14:42:27 Seeking Alpha
   22nd Century Group and Tenax Therapeutics among healthcare gainers; Ligand Pharmaceuticals and Endologix among the losers  2019/03/06 16:06:16 Seeking Alpha

calendar